TABLE 1. Baseline demographic, clinical, and laboratory characteristics of the 43,079 vaccinated patients with CLDs with and without cirrhosis.
| Vaccinated CLD Without Cirrhosis (n = 32,838) | Vaccinated CLD With Cirrhosis (n = 10,241) | p value | |
|---|---|---|---|
| Female | 17,909 (55) | 4743 (46) | <0.01 |
| Age (years) | 57 (45–66) | 61 (53–69) | <0.01 |
| 18–29 | 1471 (4) | 213 (2) | |
| 30–49 | 9135 (28) | 1765 (17) | |
| 50–64 | 12,826 (39) | 4256 (42) | |
| 65+ | 9406 (29) | 4007 (39) | |
| Race/ethnicity | <0.01 | ||
| White | 16,528 (50) | 5690 (56) | |
| Black/African‐American | 5073 (15) | 1725 (17) | |
| Hispanic | 6938 (21) | 1851 (18) | |
| Asian | 1931 (6) | 334 (3) | |
| Unknown/Other | 2368 (7) | 641 (6) | |
| Height (cm) | 168 (160–175) | 170 (163–178) | <0.01 |
| Weight (kg) | 88 (73–104) | 83 (69–100) | <0.01 |
| BMI (kg/m2) | 31 (27–36) | 29 (25–34) | <0.01 |
| Liver disease etiology | <0.01 | ||
| NAFLD | 22,817 (69) | 3549 (35) | |
| Hepatitis C | 6230 (19) | 2036 (20) | |
| AALD | 1205 (4) | 2995 (29) | |
| Hepatitis B | 1998 (6) | 514 (5) | |
| Cholestatic | 159 (0) | 697 (7) | |
| Autoimmune | 429 (1) | 450 (4) | |
| Decompensated cirrhosis | 0 (0) | 6287 (61) | |
| Modified Charlson Indexa | 1 (0–3) | 2 (1–5) | <0.01 |
| Region | <0.01 | ||
| Northeast | 3981 (12) | 910 (9) | |
| Midwest | 5254 (16) | 2155 (21) | |
| South | 5071 (15) | 1915 (19) | |
| West | 7261 (22) | 2090 (20) | |
| Other | 11,271 (34) | 3171 (31) | |
| MELD‐Nab | 9 (7–12) | 14 (10–20) | <0.01 |
| Initial vaccine type | <0.01 | ||
| BNT162b2 | 21,040 (64) | 6909 (67) | |
| mRNA‐1273 | 10,304 (31) | 2802 (27) | |
| JNJ‐784336725 | 1494 (5) | 530 (5) | |
| Total no. of doses | <0.01 | ||
| 1 | 5603 (17) | 2023 (20) | |
| 2 | 20,923 (64) | 6418 (63) | |
| 3+ | 6312 (19) | 1800 (18) | |
| Breakthrough COVID cases | 1290 (4) | 379 (4) | 0.31 |
Note: Continuous variables are described as medians with IQRs in parentheses; ordinal and categorical variables are described as counts with percentages in parentheses.
a
Modified Charlson Index was calculated based on the original Charlson Comorbidity Score excluding weights for mild liver disease and severe liver disease.
b
MELD‐Na scores were calculated for ~16% of the total sample.